PROMOMED and the Russian Society of Clinical Oncology will join forces to combat cancer

The signed memorandum implies comprehensive cooperation in the development of the pharmaceutical industry and medicine. The efforts of the parties will be aimed at the fight, prevention, diagnosis and treatment of cancer.

"Today, the Russian pharmaceutical industry is making every effort to build technological sovereignty and strengthen the health of Russians. According to the Ministry of Health, currently more than 4 million citizens suffer from cancer, and the annual increase is 600 thousand patients. The world practice includes countless innovative treatment regimens for malignant neoplasms (ZN). They cannot be fully implemented: no national healthcare system in the world can withstand this. Therefore, we must focus our efforts on creating and using our own technologies in the development of drugs for the treatment of hypertension. Without this, we will not be able to achieve drug sovereignty. In this context, the interaction of drug developers and the medical community, scientists and manufacturers is of strategic importance. The synergetic effect of such cooperation will allow us to find new solutions in the field of developing tools for the treatment, therapy, diagnosis, and prevention of oncological diseases," said Ilya Bardin-Denisov, CEO of PROMOMED DM LLC.

RUSSCO and Promomed Group of Companies have agreed to combine efforts in the field of scientific and clinical research, professional development of specialists, development and implementation of innovative drugs.

"We expect that the cooperation of the professional community and the developer will contribute to the early launch of new medicines on the market, which are necessary for the treatment of cancer patients. The drugs will not only be able to find their place, but also go through the process of implementation in real clinical practice as quickly as possible. We expect that this cooperation will bring positive results to all parties: patients, the professional community, developers and manufacturers," said Sergey Tyulandin, Honored Scientist of the Russian Federation, Chief Researcher at the Department of Antitumor Drug Therapy No. 2 of the Blokhin National Research Medical Center of Oncology of the Russian Ministry of Health, Member of the Board of RUSSCO.

Promomed Group offers the oncological community its own experience, which can form the basis of scientific and educational programs, practical recommendations and methodological materials. Cooperation involves comprehensive support in the development and implementation of strategies for early diagnosis and prevention of cancer.